Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 254

1.

Extended adjuvant endocrine therapy in hormone-receptor positive breast cancer.

Strasser-Weippl K, Badovinac-Crnjevic T, Fan L, Goss PE.

Breast. 2013 Aug;22 Suppl 2:S171-5. doi: 10.1016/j.breast.2013.07.033. Review.

PMID:
24074782
2.

Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.

Jankowitz RC, McGuire KP, Davidson NE.

Breast. 2013 Aug;22 Suppl 2:S165-70. doi: 10.1016/j.breast.2013.07.032. Review.

PMID:
24074781
3.

Postmenopausal women with hormone receptor-positive breast cancer: balancing benefit and toxicity from aromatase inhibitors.

Ingle JN.

Breast. 2013 Aug;22 Suppl 2:S180-3. doi: 10.1016/j.breast.2013.07.035. Review.

PMID:
24074784
4.

Letrozole in the neoadjuvant setting: the P024 trial.

Ellis MJ, Ma C.

Breast Cancer Res Treat. 2007;105 Suppl 1:33-43. Epub 2007 Oct 3. Erratum in: Breast Cancer Res Treat. 2008 Nov;112(2):371.

5.

Beyond tamoxifen: extended and late extended endocrine therapy in postmenopausal early breast cancer.

Dodwell D, Williamson D.

Cancer Treat Rev. 2008 Apr;34(2):137-44. Epub 2007 Nov 14. Review.

PMID:
18006236
6.

Letrozole in the extended adjuvant setting: MA.17.

Goss PE.

Breast Cancer Res Treat. 2007;105 Suppl 1:45-53. Epub 2007 Oct 3. Erratum in: Breast Cancer Res Treat. 2008 Nov;112(2):369.

7.

Challenges in the endocrine management of breast cancer.

Mouridsen HT, Rose C, Brodie AH, Smith IE.

Breast. 2003 Aug;12 Suppl 2:S2-19. Review.

PMID:
14659138
8.

Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE.

Am J Manag Care. 2006 Jul;12(7):374-86.

9.

Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17/BIG 1-97 trial.

Higgins MJ, Liedke PE, Goss PE.

Crit Rev Oncol Hematol. 2013 Apr;86(1):23-32. doi: 10.1016/j.critrevonc.2012.09.013. Epub 2012 Oct 30. Review.

PMID:
23116626
10.

Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.

Gradishar WJ.

Oncology. 2005;69(1):1-9. Epub 2005 Jul 28. Review.

PMID:
16088229
11.

Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?

Kaufmann M, Rody A.

Eur J Obstet Gynecol Reprod Biol. 2006 Jun 1;126(2):146-54. Epub 2006 Apr 18. Review.

PMID:
16621229
12.

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.

Breast International Group (BIG) 1-98 Collaborative Group, Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A.

N Engl J Med. 2005 Dec 29;353(26):2747-57. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. Wardly, Andrew [corrected to Wardley, Andrew ].

13.

Choosing early adjuvant therapy for postmenopausal women with hormone-sensitive breast cancer: aromatase inhibitors versus tamoxifen.

Carpenter R.

Eur J Surg Oncol. 2008 Jul;34(7):746-55. doi: 10.1016/j.ejso.2008.01.011. Epub 2008 Mar 4. Review.

PMID:
18296017
14.

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.

Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups.

Lancet Oncol. 2008 Jan;9(1):23-8. Epub 2007 Dec 20.

PMID:
18083065
15.

Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a.

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group.

J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226.

PMID:
18073378
16.

Obesity and endocrine therapy: host factors and breast cancer outcome.

Goodwin PJ.

Breast. 2013 Aug;22 Suppl 2:S44-7. doi: 10.1016/j.breast.2013.07.008. Review.

PMID:
24074791
17.

Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in hormone receptor-positive postmenopausal women with early-stage breast cancer.

Delea TE, Karnon J, Sofrygin O, Thomas SK, Papo NL, Barghout V.

Clin Breast Cancer. 2007 Jun;7(8):608-18.

PMID:
17592673
18.

Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Amir E, Seruga B, Niraula S, Carlsson L, Ocaña A.

J Natl Cancer Inst. 2011 Sep 7;103(17):1299-309. doi: 10.1093/jnci/djr242. Epub 2011 Jul 9. Review.

PMID:
21743022
19.

Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.

Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A.

J Clin Oncol. 2007 Feb 10;25(5):486-92. Epub 2007 Jan 2.

PMID:
17200148
20.

Initialization of adjuvant hormonal treatment for breast cancer.

Martínez Guisado A, Sánchez Muñoz A, de la Cabeza Lomas Garrido M, Ruíz Borrego M, Bayo Calero J, de Toro Salas R, González Mancha R, de la Haba Rodríguez J, Alba Conejo E.

Adv Ther. 2011 Sep;28 Suppl 6:66-84. doi: 10.1007/s12325-011-0039-8. Epub 2011 Sep 16. Review.

PMID:
21922396

Supplemental Content

Support Center